JP2020518582A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518582A5
JP2020518582A5 JP2019559304A JP2019559304A JP2020518582A5 JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5 JP 2019559304 A JP2019559304 A JP 2019559304A JP 2019559304 A JP2019559304 A JP 2019559304A JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5
Authority
JP
Japan
Prior art keywords
crystalline
hydrate
pharmaceutical composition
succinate
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518582A (ja
JP7096268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030144 external-priority patent/WO2018204236A1/en
Publication of JP2020518582A publication Critical patent/JP2020518582A/ja
Publication of JP2020518582A5 publication Critical patent/JP2020518582A5/ja
Application granted granted Critical
Publication of JP7096268B2 publication Critical patent/JP7096268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559304A 2017-05-01 2018-04-30 Jak阻害剤化合物の結晶形態 Expired - Fee Related JP7096268B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492571P 2017-05-01 2017-05-01
US62/492,571 2017-05-01
PCT/US2018/030144 WO2018204236A1 (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Publications (3)

Publication Number Publication Date
JP2020518582A JP2020518582A (ja) 2020-06-25
JP2020518582A5 true JP2020518582A5 (https=) 2021-05-06
JP7096268B2 JP7096268B2 (ja) 2022-07-05

Family

ID=62165729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559304A Expired - Fee Related JP7096268B2 (ja) 2017-05-01 2018-04-30 Jak阻害剤化合物の結晶形態

Country Status (13)

Country Link
US (1) US10251874B2 (https=)
EP (1) EP3619208B1 (https=)
JP (1) JP7096268B2 (https=)
KR (1) KR20200003121A (https=)
CN (1) CN110603255B (https=)
AU (1) AU2018261591B2 (https=)
CA (1) CA3059790A1 (https=)
MX (1) MX389014B (https=)
MY (1) MY200348A (https=)
PH (1) PH12019502425A1 (https=)
SG (1) SG11201909376TA (https=)
TW (1) TWI808083B (https=)
WO (1) WO2018204236A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022204473A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
EP4359402B1 (en) 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
UA123633C2 (uk) * 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2020518582A5 (https=)
JP2023516640A5 (https=)
JP2020518581A5 (https=)
JP2021535177A5 (https=)
JP5416408B2 (ja) 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドの新規多形および無定形
JP2021535174A5 (https=)
JP2016500111A5 (https=)
CN112638877B (zh) 用于治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物
JP2021504338A5 (https=)
JP2012532112A5 (https=)
JP2022502500A5 (https=)
JP2013542937A5 (https=)
JP2021527031A5 (https=)
JP2013538857A5 (https=)
JP2019509268A5 (https=)
JP2016529306A5 (https=)
JP2019505529A5 (https=)
TW200304824A (en) Nicotinamide derivatives useful as PDE4 inhibitors
JP2020521732A5 (https=)
RU2014135759A (ru) Конденсированные пирролдикарбоксамиды и их применение в качестве фармацевтических средств
JP2013542267A5 (https=)
RU2003131178A (ru) Агонисты никотиновых рецепторов для лечения воспалительных заболеваний
JP2022533340A5 (https=)
JP2023500263A5 (https=)
WO2014063199A1 (en) Organic compounds